NATIONAL INSTITUTES OF HEALTH
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Phase 2
Completed
- Conditions
- Fallopian Tube CancerFemale Reproductive CancerOvarian SarcomaStage IV Uterine SarcomaUterine CarcinosarcomaUterine LeiomyosarcomaStage III Uterine SarcomaStage IV Ovarian Epithelial CancerOvarian CarcinosarcomaRecurrent Ovarian Epithelial Cancer
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00390234
- Locations
- π¨π¦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
π¨π¦Vancouver General Hospital, Vancouver, British Columbia, Canada
π¨π¦McGill University Department of Oncology, Montreal, Quebec, Canada
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
Phase 2
Terminated
- Conditions
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesMast Cell LeukemiaMeningeal Chronic Myelogenous LeukemiaPrimary MyelofibrosisProgressive Hairy Cell Leukemia, Initial TreatmentAccelerated Phase Chronic Myelogenous LeukemiaAcute Undifferentiated LeukemiaAdult Acute Myeloid Leukemia in Remission
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT00387426
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase 2
Completed
- Conditions
- Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IV Squamous Cell Carcinoma of the Lip and Oral CavityMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the Larynx
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT00387335
- Locations
- πΊπΈ
University of Chicago, Chicago, Illinois, United States
Sunitinib in Treating Young Patients With Refractory Solid Tumors
Phase 1
Completed
- Conditions
- Childhood Central Nervous System Embryonal TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaCentral Nervous System MetastasesChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Yolk Sac TumorRecurrent Childhood Central Nervous System Embryonal TumorUnspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- Other: pharmacological studyProcedure: dynamic contrast-enhanced magnetic resonance imagingOther: laboratory biomarker analysis
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00387920
- Locations
- π¨π¦
Hospital for Sick Children, Toronto, Ontario, Canada
πΊπΈChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
πΊπΈChildren's National Medical Center, Washington, District of Columbia, United States
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Phase 2
Completed
- Conditions
- Recurrent MelanomaStage III Skin MelanomaStage IV Skin Melanoma
- Interventions
- Biological: BevacizumabOther: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT00387751
- Locations
- πΊπΈ
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States
Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma
Phase 2
Completed
- Conditions
- Untreated Childhood Brain Stem Glioma
- Interventions
- Radiation: 3-dimensional conformal radiation therapy
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00387790
- Locations
- πΊπΈ
Children's Oncology Group, Philadelphia, Pennsylvania, United States
Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerStage IIIA Ovarian Epithelial CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian Epithelial CancerStage IV Primary Peritoneal Cavity CancerStage IIIA Fallopian Tube CancerStage IIIA Primary Peritoneal Cavity CancerStage IIIB Fallopian Tube CancerStage IIIB Primary Peritoneal Cavity Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00388037
- Locations
- π¨π¦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab
Phase 2
Completed
- Conditions
- Drug/Agent Toxicity by Tissue/OrganStage IIIB Non-small Cell Lung CancerAdenosquamous Cell Lung CancerHemoptysisSquamous Cell Lung CancerStage IV Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT00387374
- Locations
California Cancer Consortium
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Recurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 94
- Registration Number
- NCT00387465
- Locations
- πΊπΈ
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈSidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
πΊπΈSidney Kimmel Cancer Center, San Diego, California, United States
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2
Terminated
- Conditions
- Recurrent Mantle Cell LymphomaRecurrent Adult Diffuse Large Cell Lymphoma
- Interventions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT00383565
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States